Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of SCAI-005 in Healthy Korean Subjects
NCT06969001Phase 1Completed
- Sponsor
- SCAI Therapeutics
- Start
- May 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of axitinib in exudative macular degeneration (2 arms), sponsored by SCAI Therapeutics. Primary endpoint: Incidence, type, and severity of Adverse Events at 15 days. Started May 2025; status: completed.
02
Drugs
axitinib
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT06969001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06969001.